• Mashup Score: 3

    PURPOSE Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC). METHODS This open-label, multicenter study (ClinicalTrials.gov identifier: NCT03786081) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) and identified the recommended phase II dose (RP2D) of TV in combination with bevacizumab (arm A), pembrolizumab (arm B), or carboplatin (arm C). The dose-expansion arms evaluated TV antitumor activity and safety at RP2D in combination with carboplatin as first-line (1L) treatment (arm D) or with pembrolizumab as 1L (arm E) or second-/third-line (2L/3L) treatment (arm F). The primary end point of dose expansion was objective response rate (ORR). RESULTS A total of 142 patients were enrolled. In dose escalation (n = 41), no DLTs were observ

    Tweet Tweets with this article
    • 👀 Tisotumab vedotin combined with chemotherapy and #Immunotherapy shows encouraging activity in recurrent #CervicalCancer. 👉 https://t.co/OUrr6uLfFE #gyncsm #ADC #ImmunoOnc https://t.co/e4IARUGGRt

  • Mashup Score: 4

    PURPOSE Despite marked advances in the treatment of unresectable or metastatic melanoma, the need for novel therapies remains. Bempegaldesleukin (BEMPEG), a pegylated interleukin-2 (IL-2) cytokine prodrug, demonstrated efficacy in the phase II PIVOT-02 trial. PIVOT IO 001 (ClinicalTrials.gov identifier: NCT03635983) is a phase III, randomized, open-label study that builds on the PIVOT-02 results in first-line melanoma. METHODS Patients with previously untreated, unresectable, or metastatic melanoma were randomly assigned 1:1 to receive BEMPEG plus nivolumab (NIVO) or NIVO monotherapy. Primary end points were objective response rate (ORR) and progression-free survival (PFS) by blinded independent central review and overall survival (OS). Secondary and exploratory end points included additional efficacy measures, safety, and pharmacokinetics (PKs) and pharmacodynamics analyses. RESULTS In 783 patients (n = 391, BEMPEG plus NIVO; n = 392, NIVO monotherapy), the median follow-up was 11.6 m

    Tweet Tweets with this article
    • 👎 PIVOT Trial: Bempegaldesleukin plus nivolumab in untreated advanced #Melanoma did not improve response or survival. ➡️ https://t.co/0ezShCQFEj #melsm #immunotherapy #ImmunoOnc https://t.co/REV41BfqVp

  • Mashup Score: 0

    Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, provides an overview of resistance mechanisms to antibody-drug conjugates (ADCs) in patients with breast cancer. Downregulation of receptors such as HER2, which is a target for trastuzumab deruxtecan, can induce resistance, and mutations in tumors can additionally result in resistance to the payload. Dr Hamilton also discusses promising combination strategies, where combining ADCs with endocrine therapies, immunotherapies, or PARP inhibitors may have a synergistic effect without a serious increase in toxicity. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Tweet Tweets with this article
    • 📣October is Breast Cancer Awareness Month 📅 Check out this interview from the #BreastCancer channel, where @ErikaHamilton9 provides an overview of resistance mechanisms to ADCs in patients with breast cancer: ➡️https://t.co/Ey3pIyUEhw🎥 #BCSM #ImmunoOnc https://t.co/ebRjwb2Vzy

  • Mashup Score: 0

    Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, discusses results from the EPCORE CLL-1 trial (NCT04623541), which is evaluating the safety and efficacy of epcoritamab in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and Richter’s transformation (RT). This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Tweet Tweets with this article
    • Always a pleasure to speak with Arnon Kater (@UvA_Amsterdam), who shared some findings from the EPCORE CLL-1 trial, which is evaluating epcoritamab in patients with R/R CLL & Richter’s transformation: 👉 https://t.co/di76OnRRcW @iwCLL #CLLsm #LeuSM #ImmunoOnc

  • Mashup Score: 2

    Jennifer M. Ahlstrom HealthTree Foundation, Lehi, UT Jennifer M. Ahlstrom, Dee Lin, Nathan W. Sweeney, Bingcao Wu, Katharine Gries, Nina Kim, Saurabh Patel, Douglas W. Sborov, Jesus G. Berdeja, Larry D. Anderson, Jr, Jinhai Huo, Jay R Hydren HealthTree Foundation, Lehi, UT, Janssen Scientific Affairs, LLC, Horsham, PA, Janssen Global Services, LLC, Raritan, NJ, Janssen US Oncology Medical Affairs, Horsham, PA, The University of Utah Huntsman Cancer Institute, Salt Lake City, UT, Sarah Cannon Research

    Tweet Tweets with this article
    • Patient perspectives on BCMA-targeted therapies for multiple myeloma: A survey conducted in a patient advocacy group [@HealthtreeMM] - @AhlstromJenny et al. #ASCO23 Abstract 2582 https://t.co/JqM8VqmgcV #mmsm #CARTcell #ImmunoOnc HT @RahulBanerjeeMD

  • Mashup Score: 2

    In this video, Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the unique toxicity profile associated with bispecific antibodies and provides guidance for physicians treating patients with non-Hodgkin lymphoma (NHL) using this class of agents. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Tweet Tweets with this article
    • We recently spoke w/ Jason Westin (@Lymphoma_Doc; @MDAndersonNews), who provided clinical guidance for the use of bispecific antibodies in NHL: 🎥 https://t.co/S1PCnzbNQr #LymSM #HemOnc #ImmunoOnc #SOHO23

  • Mashup Score: 0

    In the article that accompanies this editorial, Nadal et al 8 present the results of a single-arm, multicenter phase II study (Atezo-Brain) investigating the safety and efficacy of atezolizumab in combination with carboplatin and pemetrexed in patients with advanced, nonsquamous non–small-cell lung cancer with clinically stable, untreated brain metastases. In addition to demonstrating the intracranial safety and efficacy of chemoimmunotherapy, even in patients with a considerable burden of intracranial

    Tweet Tweets with this article
    • 📣 #JCO #Editorial: Chemoimmunotherapy for untreated #LungCancer brain metastases: Systemic before local therapy? https://t.co/mhHTzqzRQq #LCSM #ImmunoOnc @Benjamin_Y_Lu @NadalErnest

  • Mashup Score: 0

    Natalie Vokes, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the EMPOWER-Lung 1 trial (NCT03088540), which investigated cemiplimab versus chemotherapy in patients with advanced, PD-L1-high non-small-cell lung cancer (NSCLC). The aim of the study was to assess the use of circulating tumor DNA (ctDNA) dynamics to understand immunotherapy responses. A clear bimodal distribution was witnessed in the immunotherapy cohort. In the chemotherapy cohort, many patients ctDNA reduced, but there was markedly less complete clearance. Patients who had a complete clearance of ctDNA had better long-term outcomes in terms of progression-free survival (PFS) and overall survival (OS). In terms of radiographic response assessments, dynamics correlated with either partial response or progressive disease. However, patients with stable disease either saw a rise or a fall in ctDNA levels. These patients could be categorized based on their ctDNA levels. Therefore, this study high

    Tweet Tweets with this article
    • 🎥@NIVokes of @MDAndersonNews reveals how circulating tumor DNA can help predict immunotherapy responses in PD-L1-high #NSCLC: ➡️https://t.co/ojdSlCQfXo #ASCO23 #LCSM #LungCancer #ImmunoOnc

  • Mashup Score: 1

    Tanya Siddiqi, MD, City of Hope, Duarte, CA, summarizes outcomes of the Phase I/II TRANSCEND-CLL-004 study (NCT03331198), which is investigating the safety and efficacy of lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). This study met its primary endpoint, and Dr Siddiqi talks on the clinical benefit of this CAR-T product in this patient population. To conclude, Dr Siddiqi highlights the curative potential of this therapy and comments on the possibility of using CAR-T cells earlier in the treatment of CLL or in combination with other agents. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Tweet Tweets with this article
    • Check out our recent interview w/ Tanya Siddiqi of @cityofhope, who summarizes outcomes of the TRANSCEND-CLL-004 study, which is evaluating liso-cel in R/R CLL: 👉 https://t.co/910pC7GWEv #LeuSM #CLLsm #CARTcell #ImmunoOnc @SocietyofHemOnc